Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved a new, highly selective alpha-1 adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia (BPH).

Silodosin Capsules (Rapaflo™)